Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.44 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28518677 | 0.93 | L3MBTL1 (0.45) | EGLN1L3MBTL1KLKB1ALKBH1GRIN1 | |
| SCHEMBL19253465 | 0.87 | L3MBTL1 (0.46) | EGLN1L3MBTL1KLKB1ALKBH1GRIN1 | |
| SCHEMBL17801254 | 0.85 | MAPT (0.50) | L3MBTL1KLKB1GRIN1GRIN2BALDH1A1 | |
| SCHEMBL22449693 | 0.81 | KLKB1 (0.48) | L3MBTL1KLKB1RAB9AALDH1A1GAA | |
| SCHEMBL14119926 | 0.80 | MAPT (0.50) | L3MBTL1NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL369349 | 0.79 | L3MBTL1 (0.58) | EGLN1L3MBTL1KLKB1ALKBH1MEN1 | |
| Hydrochloric Acid SCHEMBL31549317 | 0.78 | L3MBTL1 (0.57) | EGLN1L3MBTL1KLKB1ALKBH1MEN1 | |
| SCHEMBL17801300 | 0.77 | L3MBTL1 (0.56) | EGLN1L3MBTL1KLKB1ALKBH1GRIN1 | |
| SCHEMBL2511099 | 0.77 | L3MBTL1 (0.56) | EGLN1L3MBTL1KLKB1ALKBH1GRIN1 | |
| SCHEMBL2511098 | 0.76 | L3MBTL1 (0.55) | EGLN1L3MBTL1KLKB1ALKBH1GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230045252-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-11472809-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | PFIZER INC. (US) | 2022-10-18 | — | — | US | disclosed |
| CN-110267960-B | Substituted pyrazolo [1,5-a ] pyrazine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-3712153-B1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER (US) | 2021-12-01 | — | — | EP | disclosed |
| US-20200399281-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-10822341-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | PFIZER INC. (US) | 2020-11-03 | — | — | US | disclosed |
| EP-3712153-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | Pfizer Inc (US) | 2020-09-23 | — | — | EP | disclosed |
| EP-3419978-B1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20190071448-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2019-03-07 | — | — | US | disclosed |
| EP-3419978-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | Pfizer Inc (US) | 2019-01-02 | — | — | EP | disclosed |
| US-10144738-B2 | Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives | PFIZER INC. (US) | 2018-12-04 | — | — | US | disclosed |
| WO-2017144995-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230045252-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | CBR3, CNR1, CCR6 | EGLN1 2768/4885L3MBTL1 1530/4885KLKB1 4840/4885 |
| US-10822341-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | CBR3, CNR1, CCR6 | EGLN1 2768/4885L3MBTL1 1530/4885KLKB1 4840/4885 |
| US-10144738-B2 | Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives | JAK1, JAK2, JAK3 | EGLN1 1173/4885L3MBTL1 2410/4885KLKB1 3421/4885 |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | CBR3, CNR1, CCR6 | EGLN1 2768/4885L3MBTL1 1530/4885KLKB1 4840/4885 |
| US-20200399281-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | CBR3, CNR1, CBR1 | EGLN1 2920/4885L3MBTL1 1343/4885KLKB1 4845/4885 |
| US-20190071448-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | CBR3, CNR1, CCR6 | EGLN1 2768/4885L3MBTL1 1530/4885KLKB1 4840/4885 |
| US-11472809-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | SYMPK, IL15, STAT6 | EGLN1 3264/4885L3MBTL1 2811/4885KLKB1 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.